La Merie Business Intelligence was established in 2002 by Ulrich Martin, MD, based on his extensive experience in the biopharmaceutical industry both as a physician specializing in pharmacology and as a co-founder and CEO of a product development biotech company. The focus of their products is directed towards therapeutic biologics, such as antibodies, proteins, peptides, vaccines and gene & cell therapy. They pay special attention to biosimilar antibodies and proteins, antibody drug conjugates, bispecific antibodies, TCR & CAR engineered antibodies, mRNA vaccines & therapeutics, oncolytic viruses and immuno-oncology in general.